Earlier cancer studies may need a second look after researchers found that a drug acts mainly on an unexpected target. An experimental cancer drug already being tested in patients appears to work mainly by blocking a different biological target from the one it was developed to inhibit. The finding emerged from brain cancer research that […]This is a curated summary.